Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

Recruiting now

Conditions studied: Lung Cancer, Sarcopenia, Toxicity

In brief

This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.

Key facts

Study ID

NCT02734069

Run by

Instituto Nacional de Cancerologia de Mexico

People needed

132

Starts

2016-02-01

Expected to finish

2027-12-01

Last updated by the study team

2025-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
• Candidates for treatment with carboplatin plus paclitaxel 1st line
• Performance status (ECOG 0-2)
• Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)
• Normal renal ultrasound prior to initiation of treatment

You may not qualify if…

• Patients with renal impairment (KDOQI 3-5)
• Patients who do not have computed tomography study at baseline
• Uncontrolled blood pressure (> 140 mmHg)
• Uncontrolled diabetes (> 130 mg / dL)
• Obstruction in kidney (s) or ureter (s)
• Dehydrated patients
• Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.> 1 month)

Where it is running

• Instituto Nacional de Cancerologia — Mexico City, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.